DIAGNOS Announces a Screening Program for Vision-Threatening Diseases (VTD) That Will Now Be Offered in Azur Retirement Residences Operated by the Cogir Management Corporation

BROSSARD, QUEBEC--(Marketwired - Jan. 21, 2015) - DIAGNOS Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announces today that a screening program for Vision-Threatening Diseases (VTD) offered to clientele in AZUR retirement residences.

The screening program, in which DIAGNOS wants to gradually introduce its VTD screening services in the 40 residences run by the management firm COGIR, will make it possible to prevent, detect and manage diseases such as age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, cataracts and others.

Mr. Martin Béland, Director of Business Development at DIAGNOS, says that he is proud of the progress that DIAGNOS has made in the area of VTDs, especially among seniors. "After having seen their parents, aunts, brothers and friends gradually lose the use of their eyes, many elderly people believe, wrongly, that such a sad state of affairs also lies in store for them. However, with the help of an innovative platform exploiting enhanced retinal images as offered by DIAGNOS, coupled with advances in medical technology and the latest pharmaceutical discoveries, many forms of treatment can now halt the progression of and, in some cases, even reverse or completely cure eye diseases."

About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including natural resources and healthcare.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information on DIAGNOS, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com.